Personalis (NASDAQ:PSNL) released its quarterly earnings results on Tuesday. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.58), Briefing.com reports. The company had revenue of $15.80 million during the quarter, compared to analyst estimates of $14.92 million. Personalis’s revenue was up 79.5% compared to the same quarter last year. Personalis updated its FY 2019 guidance to EPS.

Personalis stock opened at $18.79 on Wednesday. The firm has a 50-day simple moving average of $21.50. Personalis has a 12-month low of $14.25 and a 12-month high of $31.88.

In other news, Director Ken Ludlum acquired 70,000 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $1,190,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

PSNL has been the subject of a number of research analyst reports. CIBC initiated coverage on Personalis in a report on Monday, July 15th. They issued an “outperform” rating and a $29.00 price target for the company. Oppenheimer initiated coverage on Personalis in a report on Monday, July 15th. They issued an “outperform” rating and a $29.00 price target for the company. Bank of America initiated coverage on Personalis in a report on Monday, July 15th. They issued a “neutral” rating and a $27.00 price target for the company. Morgan Stanley initiated coverage on Personalis in a report on Monday, July 15th. They issued an “overweight” rating and a $28.00 price target for the company. Finally, Cowen initiated coverage on Personalis in a report on Monday, July 15th. They issued an “outperform” rating for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $28.25.

Personalis Company Profile

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.

See Also: Hold Rating

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.